Edesa Biotech Inc（EDSA）のニュースとイベントEDSAEdesa Biotech Inc

Edesa Biotech Receives FDA Approval for EB06 Clinical Study

Edesa Biotech reported that the FDA has cleared the company's investigational new drug, or IND, application for its Phase 2 clinical study of EB06 in vitiligo, enabling Edesa to expand recruitment to the United States. Patient recruitment is underway in Canada and the first U.S. investigational sites are expected to begin enrolling subjects next quarter. Edesa anticipates that topline data will be available fourth quarter 2027.

Edesa Biotech Commences Underwritten Public Offering of Common Shares

Edesa Biotech announced that it has commenced an underwritten public offering of its common shares and accompanying common share warrants to purchase common shares. All common shares, pre-funded warrants and accompanying common share warrants are being offered by Edesa. Edesa intends to use the net proceeds from the proposed offering for general corporate purposes, which may include working capital, capital expenditures and research and development and manufacturing expenses. Guggenheim Securities is acting as the sole book-running manager for the proposed offering.

Edesa Biotech Files to Sell 729,241 Common Shares

Edesa Biotech files to sell 729,241 common shares for holders